Review Sparks Calls for ‘High-Quality’ and ‘Balanced’ Research on Medical Cannabis

A comprehensive JAMA review of more than 2,500 papers (with >120 prioritized studies) led by UCLA Health finds that pharmaceutical-grade cannabinoids have proven benefit only for a narrow set of indications—FDA‑approved uses such as HIV/AIDS-related appetite loss, chemotherapy-induced nausea and certain pediatric seizure disorders (Dravet and Lennox‑Gastaut syndromes)—while evidence for most common uses, including chronic pain, anxiety and insomnia, is inconclusive or lacking; more than half of medical cannabis users cite chronic pain yet clinical guidelines do not support cannabis-based medicines as first‑line therapy. The authors warn of potential cardiovascular, psychosis and drug‑interaction risks and acknowledge limitations in their review (no formal risk‑of‑bias assessment, heterogenous study designs), while other researchers criticize the review’s selection transparency and say it may overemphasize negative findings. All parties concur that high‑quality, long‑term randomized trials and robust real‑world evidence (researchers note initiatives such as the UK Medical Cannabis Registry with >50,000 patients) and more funded research are needed to close the evidence gap and inform clinical guidance.

Analysis

A JAMA-led comprehensive review of more than 2,500 articles published from January 2010 to September 2025, with over 120 studies prioritized for relevance, concludes that pharmaceutical-grade cannabinoids show demonstrated effectiveness only for a narrow set of FDA-recognized indications: HIV/AIDS-related appetite loss, chemotherapy-induced nausea and vomiting, and specific severe pediatric seizure disorders such as Dravet and Lennox-Gastaut syndromes. For most common uses—including chronic pain, anxiety and insomnia—the review finds the evidence to be “inconclusive or lacking,” even though more than half of medical cannabis users report using it for chronic pain and current clinical guidelines advise against cannabis-based medicines as first-line therapy for that indication.

The review flags potential safety concerns, recommending clinicians screen for cardiovascular disease and psychotic disorders and evaluate drug interactions before prescribing THC-containing products, and acknowledges methodological limitations including heterogeneous study designs and the absence of a formal risk-of-bias assessment. External commentators led by Dr Simon Erridge contend the JAMA paper may understate positive findings due to selection-transparency issues and cite the 2023 BMJ umbrella review as having clearer methodology.

Both camps agree on the central implication for the sector: high-quality, long-term randomized trials and robust real-world evidence (notably the UK Medical Cannabis Patient Registry with >50,000 patients) are required to close the evidence gap and materially change clinical guidance and commercial prospects for medical cannabis products.

Key Decisions for Investors

• Reduce conviction in pure-play cannabis therapeutics reliant on off-label chronic pain demand until randomized trials or regulatory approvals broaden indications,
• Favor companies with FDA-approved cannabinoid products or diversified revenue profiles and avoid those dependent on THC-containing products facing safety screening and potential regulatory scrutiny,
• Monitor near-term catalysts: publication of high-quality RCTs, formal regulatory guidance, and registry-derived real-world evidence (e.g., UK Medical Cannabis Registry data) as triggers to reassess exposure,
• If maintaining exposure, hedge downside by limiting position size or using options protection given methodological uncertainty and the review's negative-leaning sentiment that may constrain commercial adoption.